Pharmaceutical

MAS-825 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval

MAS-825 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

Jun 18, 2024 - 04:00
MAS-825 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).
Read the original article

Tags:

Previous Article

Olanzapine ER by Teva Pharmaceutical Industries for Schizophrenia: Likelihood of...

Next Article

OCT-461201 by Oxford Cannabinoid Technologies for Visceral Pain: Likelihood of A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

City of Hope develops cell therapy for ovarian cancer

City of Hope develops cell therapy for ovarian cancer

Aug 12, 2023

STAT+: Flawed AI algorithms can cause harm in medicine. A research team has a plan to root out bias

STAT+: Flawed AI algorithms can cause harm in medicine....

Apr 13, 2023

UK rejoins EU’s Horizon Europe science programme

UK rejoins EU’s Horizon Europe science programme

Sep 7, 2023